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Mesenchymal stem cells (MSCs) are gaining importance among clinicians following recent demonstration 
of safe allogeneic transplantation due to their ability to modulate the immune response. However, the 
molecular machinery regulating the expression of immunomodulatory factors in MSCs is unknown. We, 
therefore, inhibited glycogen synthase kinase-3 (GSK-3), a Wnt signaling inhibitor, to elucidate the role 
of Wnt signaling in mediating immunoregulatory effects of human MSCs using gene expression profiling. 
Our results highlight enhanced ability of GSK-3 inhibitor (lithium) treated MSCs to evade immune 
response as a result of decreased expression of immune stimulatory cytokines and chemokines. 
 
Mesenchymal stem cells isolated from bone marrow cells are capable of in vitro expansion 
and have been demonstrated to differentiate not only into osteoblast, chondrocyte, adipocyte, 
fibroblast, tendenocyte and myoblast but undergo transdifferentiation into cardiomyocyte, 
hepatocyte, neuronal and endothelial cells in vitro (Satija et al, 2009). Their pluripotent 
character (depicted in comparison to other stem cells, Figure 1), lack of expression of MHC-
II molecules (Le Blanc et al, 2003) and recently studies documenting clinical safety (Koc et 
al, 2002) have brought MSCs to the forefront in the field of regenerative medicine. 
 
MSCs being present in the bone marrow have been identified to constitute part of 
hematopoietic niche and influence hematopoietic stem cell (HSC) fate (Mendez-Ferrer et al, 
2010). Apart from direct cell-cell contact, MSCs secrete a variety of growth factors and 
cytokines known to regulate HSC, their progeny and modulate immune cell function 
(Majumdar et al, 2000; Pedemonte et al, 2007). However, hypoimmunogenecity of MSCs 
attributed to lack of MHC class-II and costimulatory molecules (CD40, CD80 and CD86) (Le 
Blanc et al, 2003; Majumdar et al, 2003) led to testing them in allogeneic situations and were 
reported to evade rejection (Ryan et al, 2005). Not only restricted to their ability to avoid 
allogeneic rejection, they are also capable of suppressing the immune response and therefore 
have been assessed in clinical trials for graft-versus-host disease but with inconsistent 
outcome (Lazarus et al, 2005; Le Blanc et al, 2008). 
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Studies have been performed to evaluate the molecular basis of MSC-mediated immune 
suppression. Since Wnt signaling plays a significant role in regulating MSC function (Luo et 
al, 2007), we performed gene expression profiling to evaluate the effect of GSK-3, a negative 
regulator of Wnt signaling, inhibition in human MSCs on the expression of  genes involved 
in immune response modulation. Early passage (p2-4) hMSCs from 3 donors were subjected 
to lithium chloride, a GSK-3 inhibitor, treatment for 7 days and microarray-based expression 
profiling was performed using Agilent Whole genome oligonucleotide array (4x44k format). 
Data normalization was done using GeneSpring GX 11 and ratios (log2 transformed) were 
computed for each donor. Genes showing atleast 20% change in expression in all the donors 
were considered for further analysis and those involved in immune response were selected 
based on GeneOntology classification. 
 
Gene expression profiling of lithium stimulated human MSCs reveals role of GSK-3 in 
regulating levels of immune-regulatory molecules. Inhibition of GSK-3 leads to a decrease in 
the synthesis of various cytokines and chemokines implicated in chemotaxis and activation of 
immune cells (Table 1). For instance, IL8, a chemotactic and activation factor for 
neutrophils, and thus involved in inflammatory responses was found to be downregulated. 
CXCL12, also known as stromal derived factor-1, implicated to play role in HSC homing to 
bone marrow (Sharma et al, 2010), acts as a strong chemoattractant for T-lymphocytes and 
monocytes. Its downregulation in hMSCs following lithium treatment is in agreement with 
study of de Boer et al (de Boer et al, 2004). The expression of other chemokines like CXCL1, 
CXCL2 and CCL20, which acts as attractant for lynphocytes, monocytes and neutrophils, is 
repressed and highlights reduced immunogenic response of MSCs. CXCL2 and IL7 
downregulation observed in our study is supported by recent study using BIO (a GSK-3 
inhibitor) treated human MSCs (Krause et al, 2010).  
 
Our data also demonstrated significant downregulation of interleukin-8 and co-stimulatory 
molecule CD86 involved in alloreactive T-cell activation (Aggarwal & Pittenger, 2005). 
However, the effect of upregulated expression of CD70, which stimulates T-cell activation, 
on MSC immune response needs to be evaluated since MSCs express low MHC class-I and 
no MHC class-II molecules. We further found downregulation of IL6 (involved in 
lymphocyte and monocyte differentiation) and IL1A (involved in inflammatory response) but 
the results were not statistically significant. Moreover, lithium treatment does not affect the 
expression levels of MHC class-I molecules (HLA-A,-B,-C,-E,-F,-H), though the effect on 
MHC class-II is inconsistent among the donors. Expression of indoleamine 2,3-dioxygenase 
(IDO), which catabolises L-Tryptophan resulting in inhibition of allogeneic T-cell responses, 
was also observed to be upregulated (1.9 fold) but not statistically significant (Meisel et al, 
2004). Increased expression of IDO is of significance since it helps in creating a local 
immune-suppressive milieu. Thus, overall these preliminary results bring to light the 
importance of Wnt/GSK-3 signaling in immunomodulatory function of hMSCs and greater 
hypoimmunogenic character of lithium-stimulated MSCs. 
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Table 1: Significantly regulated secreted or surface expressing genes involved in modulation of 
immune cell response 
Gene 
Symbol 
Description Function Avg fold 
change 
(log2) 
p value 
IL8 interleukin 8 Inflammatory -2.99 0.002 
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal 
cell-derived factor 1) 
Chemoattracttant for 
lymphocytes & monocytes 
-1.99 0.011 
CXCL1 chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha) 
Inflammatory, chemoattract-
tant for neutrophils 
-1.58 0.000 
CCL20 chemokine (C-C motif) ligand 20 Chemoattractant for 
lymphocytes 
-1.55 0.013 
CD86 CD86 molecule Co-stimulatory for T-cell 
activation 
-1.32 0.010 
EREG epiregulin Proinflammatory -1.25 0.039 
CFI complement factor I Inhibitor of complement -1.20 0.010 
IL7 interleukin 7 Mitogenic for B- and T-cells -1.08 0.023 
CXCL2 chemokine (C-X-C motif) ligand 2 Chemoattractant for 
leukocytes 
-0.87 0.025 
CD70 CD70 molecule T-cell activation 1.53 0.026 
 
Figure 1: Stem Cell Zodiac. A diagrammatic representation of stem cell and different transcription 
factors regulating their differentiation into different cells/tissue types.  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
51
2.
1 
: P
os
te
d 
7 
Ja
n 
20
11
Acknowledgement: 
We are thankful to Dr R.P.Tripathi, Director, Institute of Nuclear Medicine and Allied Sciences, 
DRDO, Lucknow Road, Delhi-110054 for providing us necessary facilities and support. Authors 
also thank the Ministry of Defense, Department of Defense Research and Development for 
research grant. Mr. Neeraj Kumar Satija in particular thanks Council for Scientific and Industrial 
Research (CSIR, India) for the award of Senior Research Fellowship towards PhD degree. 
References: 
Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, Scadden 
DT, Ma’ayan A, Enikolopov GN, Frenette PS. Mesenchymal and haematopoietic stem cells form 
a unique bone marrow niche. Nature 2010; 466: 829-834. 
Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F, Sharma M, Sharma P, Tripathi 
RP, Gurudutta GU. Mesenchymal stem cell-based therapy: a new paradigm in regenerative 
medicine. J Cell Mol Med 2009; 13: 4385-4402. 
Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrow-derived 
mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term 
hematopoiesis when differentiated towards stromal and osteogenic lineages. J Hematother Stem 
Cell Res. 2000; 9: 841-848. 
Pedemonte E, Benvenuto F, Casazza S, Mancardi G, Oksenberg JR, Uccelli A, Baranzini SE. 
The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the 
hematopoietic stem cell niche synapse. BMC Genomics 2007; 8: 65. 
Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and 
immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp 
Hematol. 2003; 31: 890-6. 
Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, Mosca 
JD. Characterization and functionality of cell surface molecules on human mesenchymal stem 
cells. J Biomed Sci. 2003; 10: 228-41. 
Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. 
J Inflamm. 2005; 2: 8. 
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo 
ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O; Developmental 
Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem 
cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. 
Lancet. 2008; 371: 1579-86. 
Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, 
Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. 
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
51
2.
1 
: P
os
te
d 
7 
Ja
n 
20
11
hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 
2005; 11: 389-98. 
de Boer J, Siddappa R, Gaspar C, van Apeldoorn A, Fodde R, van Blitterswijk C. Wnt signaling 
inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 2004; 34: 818-826. 
Koc ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of 
metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow 
Transplant 2002; 30: 215-222. 
Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA, Tang N, Haydon RC, Luu HH, He TC. 
Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 2007; 87: 
97-103. 
Sharma M, Afrin F, Satija NK, Tripathi RP, Gurudutta GU. SDF-1/CXCR4 signaling: 
indispensable role in homing and engraftment of hematopoietic stem cells in bone marrow. Stem 
Cell Dev. 2010 (in press). 
Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N, Gregory CA. Pharmaceutical 
modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive 
therapy. Proc Natl Acad Sci USA 2010; 107: 4147-4152. 
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell 
responses. Blood 2005; 105: 1815-1822. 
Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell 
responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 
4619-4621. 
-END- 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
51
2.
1 
: P
os
te
d 
7 
Ja
n 
20
11
